Aravive (ARAV) News Today → AI “wealth window” is closing June 25th (From Paradigm Press) (Ad) Free ARAV Stock Alerts $0.04 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of Legalfinance.yahoo.com - April 23 at 2:08 PMDiabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsightfinance.yahoo.com - April 2 at 2:02 AMTelo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USfinance.yahoo.com - January 30 at 1:51 PMCrude Oil Rises Over 1%; Processa Pharmaceuticals Shares Slidemsn.com - January 18 at 2:09 PMWhy Is Nuvve (NVVE) Stock Down 31% Today?msn.com - January 18 at 9:08 AMWhy Is Aravive (ARAV) Stock Down 52% Today?markets.businessinsider.com - January 18 at 9:08 AMAravive Shares Drop 53%, Company to Delist and Deregister Stockmarketwatch.com - January 17 at 7:36 PMAravive, Inc. to Delist from The Nasdaq Stock Marketfinance.yahoo.com - January 17 at 7:36 PMmarketbeat.com - January 17 at 4:10 PMAravive Stock (NASDAQ:ARAV), Short Interest Reportbenzinga.com - December 27 at 6:16 PMAravive Stock (NASDAQ:ARAV) Dividends: History, Yield and Datesbenzinga.com - December 27 at 6:16 PMHouston is building it. Why won't they come?bizjournals.com - December 8 at 8:20 AMHouston companies, universities win nearly $50.7 million in latest CPRIT awardsbizjournals.com - November 20 at 5:55 PMAravive Inc ARAVmorningstar.com - November 12 at 6:26 PMAravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?finance.yahoo.com - October 13 at 5:44 PMAravive, Inc. (ARAV) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - September 24 at 9:12 AMThinking about buying stock in Limbach Holdings, Aravive, Up Fintech Holding, YS Biopharma, or Big Lots?benzinga.com - August 29 at 5:17 PMCantor Fitzgerald Downgrades Aravive247wallst.com - August 23 at 6:05 PMCantor Fitzgerald Downgrades Aravive (ARAV)msn.com - August 22 at 10:01 PMCantor cuts Aravive to neutral as biotech struggles to stay in businessmsn.com - August 22 at 5:01 PMAnalyst Downgrades Aravive: Grapples With Trial Setback, Strategic Alternativesmarkets.businessinsider.com - August 22 at 5:01 PMWilliam Blair Downgrades Aravive (ARAV)msn.com - August 4 at 1:51 AMAravive (ARAV) Price Target Decreased by 5.77% to 12.50msn.com - August 3 at 8:10 PMAravive sinks as Phase 3 ovarian cancer trial for lead asset failsseekingalpha.com - August 3 at 3:10 PMAravive Shares Hit 52-Week Low After Trial Misses Primary Endpointmarketwatch.com - August 3 at 3:10 PMAravive (NASDAQ:ARAV) Plummets On Phase 3 Disappointment In Ovarian Cancermsn.com - August 3 at 3:10 PMH.C. Wainwright downgrades Aravive (ARAV) to a Holdmarkets.businessinsider.com - August 3 at 10:10 AMWhy Is Aravive Stock Sinking Today?msn.com - August 3 at 10:10 AMAravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancerfinance.yahoo.com - August 3 at 10:10 AMWhy Is Aravive (ARAV) Stock Down 58% Today?investorplace.com - August 3 at 10:04 AMmarketbeat.com - August 2 at 4:02 PMAravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023finance.yahoo.com - July 28 at 8:55 AMAravive (NASDAQ:ARAV) Rating Reiterated by Cantor Fitzgeraldmarketbeat.com - July 21 at 10:15 AMAravive, Inc.'s (NASDAQ:ARAV) largest shareholders are private equity firms with 50% ownership, individual investors own 22%finance.yahoo.com - July 19 at 7:20 AMAravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023finance.yahoo.com - July 14 at 7:22 AMCantor Fitzgerald Reiterates Overweight on Aravive, Maintains $18 Price Targetbenzinga.com - July 3 at 5:24 PMThe Latest Analyst Ratings for Aravivemarkets.businessinsider.com - July 3 at 5:24 PMPediatric Growth Hormone Deficiency Market expected to rise | Companies – Ascendis Pharma, OPKO Health, Aravive, expected to drive marketbenzinga.com - July 3 at 12:23 PMARAV Jul 2023 7.500 callfinance.yahoo.com - June 20 at 6:05 PMAravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)finance.yahoo.com - June 13 at 6:06 PMAravive To Participate in the Jefferies Global Healthcare Conferencefinance.yahoo.com - June 5 at 7:13 PMEF Hutton Keeps Their Buy Rating on Aravive (ARAV)markets.businessinsider.com - June 5 at 9:12 AMH.C. Wainwright Sticks to Its Buy Rating for Aravive (ARAV)markets.businessinsider.com - June 5 at 9:12 AMAravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023finance.yahoo.com - May 25 at 5:29 PMAnalysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Aravive (ARAV) and Cyclacel Pharmaceuticals (CYCC)markets.businessinsider.com - May 25 at 12:28 PMAnalyst Expectations for Aravive's Futuremsn.com - May 25 at 12:28 PMAravive: Very Small Company With Late Stage Trial In Ovarian Cancermsn.com - May 24 at 9:40 AM7 Short-Interest Stocks to Target for Explosive Gainsmarkets.businessinsider.com - May 18 at 4:59 PMCantor Fitzgerald Reiterates Aravive (ARAV) Overweight Recommendationmsn.com - May 18 at 6:58 AMAravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinomafinance.yahoo.com - May 16 at 9:36 AM Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address The Weight Loss Pill That Could Disrupt a $32 Billion Industry (Ad)A revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results. Don't miss out on the "next Ozempic" >>> ARAV Media Mentions By Week ARAV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARAV News Sentiment▼0.000.36▲Average Medical News Sentiment ARAV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARAV Articles This Week▼01▲ARAV Articles Average Week Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ATXI News Today BPTS News Today ARDS News Today AGRX News Today CYCC News Today CLVR News Today VRPX News Today PHIO News Today GOVX News Today SXTP News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARAV) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityWatch this FREE trading tutorial while it’s still availableInvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
